Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules.

Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW.

J Clin Endocrinol Metab. 2011 Nov;96(11):E1719-26. doi: 10.1210/jc.2011-0459. Epub 2011 Aug 24.

PMID:
21865367
2.

Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.

Vriens D, Adang EM, Netea-Maier RT, Smit JW, de Wilt JH, Oyen WJ, de Geus-Oei LF.

J Clin Endocrinol Metab. 2014 Sep;99(9):3263-74. doi: 10.1210/jc.2013-3483. Epub 2014 May 29.

PMID:
24873995
3.

Cost-effectiveness of using a molecular diagnostic test to improve preoperative diagnosis of thyroid cancer.

Najafzadeh M, Marra CA, Lynd LD, Wiseman SM.

Value Health. 2012 Dec;15(8):1005-13. doi: 10.1016/j.jval.2012.06.017. Epub 2012 Sep 25.

4.

Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis.

Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA.

J Clin Endocrinol Metab. 2008 Jun;93(6):2173-80. doi: 10.1210/jc.2007-2496. Epub 2008 Mar 25.

PMID:
18364376
5.

Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology.

Lee L, How J, Tabah RJ, Mitmaker EJ.

J Clin Endocrinol Metab. 2014 Aug;99(8):2674-82. doi: 10.1210/jc.2014-1219. Epub 2014 Mar 31.

PMID:
24684467
6.

Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.

Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR.

N Engl J Med. 2012 Aug 23;367(8):705-15. doi: 10.1056/NEJMoa1203208. Epub 2012 Jun 25.

7.

Cost-Effectiveness of Diagnostic Lobectomy Versus Observation for Thyroid Nodules >4 cm.

Lee L, Mitmaker EJ, Chabot JA, Lee JA, Kuo JH.

Thyroid. 2016 Feb;26(2):271-9. doi: 10.1089/thy.2015.0300. Epub 2016 Jan 22.

PMID:
26715288
8.

The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology.

Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB, McIver B.

Thyroid. 2012 Oct;22(10):996-1001. doi: 10.1089/thy.2012.0180. Epub 2012 Aug 8.

9.

Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?

Kloos RT, Reynolds JD, Walsh PS, Wilde JI, Tom EY, Pagan M, Barbacioru C, Chudova DI, Wong M, Friedman L, LiVolsi VA, Rosai J, Lanman RB, Kennedy GC.

J Clin Endocrinol Metab. 2013 Apr;98(4):E761-8. doi: 10.1210/jc.2012-3762. Epub 2013 Mar 8.

PMID:
23476074
10.

Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology.

Labourier E.

Clin Endocrinol (Oxf). 2016 Oct;85(4):624-31. doi: 10.1111/cen.13096. Epub 2016 Jun 3.

PMID:
27155136
11.

Routine on-site evaluation of specimen adequacy during initial ultrasound-guided fine needle aspiration of thyroid nodules: a cost-effectiveness analysis.

Zanocco K, Pitelka-Zengou L, Dalal S, Elaraj D, Nayar R, Sturgeon C.

Ann Surg Oncol. 2013 Aug;20(8):2462-7. doi: 10.1245/s10434-013-2954-1. Epub 2013 Mar 26.

PMID:
23529781
12.

Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies.

Yip L, Farris C, Kabaker AS, Hodak SP, Nikiforova MN, McCoy KL, Stang MT, Smith KJ, Nikiforov YE, Carty SE.

J Clin Endocrinol Metab. 2012 Jun;97(6):1905-12. doi: 10.1210/jc.2011-3048. Epub 2012 Mar 14.

13.

Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.

Gould MK, Sanders GD, Barnett PG, Rydzak CE, Maclean CC, McClellan MB, Owens DK.

Ann Intern Med. 2003 May 6;138(9):724-35.

PMID:
12729427
14.

Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules.

Ferraz C, Eszlinger M, Paschke R.

J Clin Endocrinol Metab. 2011 Jul;96(7):2016-26. doi: 10.1210/jc.2010-2567. Epub 2011 May 18. Review.

PMID:
21593119
15.

Molecular diagnostics for thyroid nodules: the current state of affairs.

Mon SY, Hodak SP.

Endocrinol Metab Clin North Am. 2014 Jun;43(2):345-65. doi: 10.1016/j.ecl.2014.02.015. Review.

PMID:
24891166
16.

An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.

McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, Kosok L, Reddi H.

J Clin Endocrinol Metab. 2014 Nov;99(11):4069-77. doi: 10.1210/jc.2013-3584. Epub 2014 Apr 29.

PMID:
24780044
17.

Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules.

Borget I, Vielh P, Leboulleux S, Allyn M, Iacobelli S, Schlumberger M, de Pouvourville G.

Am J Clin Pathol. 2008 May;129(5):763-71. doi: 10.1309/H86KM785Q9KBWPW5.

PMID:
18426737
18.

Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance.

Balentine CJ, Vanness DJ, Schneider DF.

Surgery. 2018 Jan;163(1):88-96. doi: 10.1016/j.surg.2017.10.004. Epub 2017 Nov 8.

19.

Overview of molecular biomarkers for enhancing the management of cytologically indeterminate thyroid nodules and thyroid cancer.

Duick DS.

Endocr Pract. 2012 Jul-Aug;18(4):611-5. doi: 10.4158/EP12065.RA. Review.

PMID:
22849877
20.

Fine-needle aspiration biopsy versus ultrasound-guided fine-needle aspiration biopsy: cost-effectiveness as a frontline diagnostic modality for solitary thyroid nodules.

Khalid AN, Quraishi SA, Hollenbeak CS, Stack BC Jr.

Head Neck. 2008 Aug;30(8):1035-9. doi: 10.1002/hed.20829.

PMID:
18442056

Supplemental Content

Support Center